Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM4B | O94953 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202594 | 0.91 | KDM4A (0.32) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL1973 | 0.72 | MAPT (0.36) | — | |
| SCHEMBL743406 | 0.72 | — | — | |
| SCHEMBL29428806 | 0.71 | KDM4A (0.39) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL30237822 | 0.71 | KDM4A (0.39) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL88851 | 0.71 | KDM4A (0.39) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Pyrazine SCHEMBL7056616 | 0.67 | HSP90AA1 (0.40) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL2511032 | 0.65 | — | — | |
| SCHEMBL16357 | 0.65 | KDM4E (0.32) | — | |
| SCHEMBL22479745 | 0.65 | KDM4E (0.39) | KDM4AKDM4BKDM5CKDM4CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 846 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024106781-A1 | LIPID COMPOUND AND COMPOSITION FOR DELIVERY OF ACTIVE SUBSTANCE | 한국생명공학연구원 | 2024-05-23 | — | — | WO | claimed |
| US-20230357268-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | NEUSCO BIOTECH LIMITED (CN) | 2023-11-09 | — | — | US | claimed |
| US-20230271980-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | NEUSCO BIOTECH LIMITED (CN) | 2023-08-31 | — | — | US | claimed |
| US-20230242532-A1 | TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | NEUSCO BIOTECH LIMITED (CN) | 2023-08-03 | — | — | US | claimed |
| US-20230212168-A1 | ENDOCYCLIC PYRIMIDINONE COMPOUNDS, AND PREPARATION METHODS, COMPOSITIONS AND USE THEREOF | NEUSCO BIOTECH LIMITED (CN) | 2023-07-06 | — | — | US | claimed |
| EP-4180436-A1 | TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | Neusco Biotech Limited (CN) | 2023-05-17 | — | — | EP | claimed |
| EP-4174070-A1 | TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | Neusco Biotech Limited (CN) | 2023-05-03 | — | — | EP | claimed |
| WO-2023049643-A1 | INHIBITORS OF SARS-COV-2 | CITY OF HOPE (US) | 2023-03-30 | — | — | WO | claimed |
| EP-4151638-A1 | BRIDGED CYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION CONTAINING SAME AND USE THEREOF | Neusco Biotech Limited (CN) | 2023-03-22 | — | — | EP | claimed |
| WO-2022001881-A1 | TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | 上海纽思克生物科技有限公司 | 2022-01-06 | — | — | WO | claimed |
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | claimed |
| US-8017612-B2 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2011-09-13 | — | — | US | claimed |
| WO-2011105628-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-01 | — | — | WO | claimed |
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | claimed |
| EP-2009004-A1 | NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2008-12-31 | — | — | EP | claimed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | claimed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | claimed |
| EP-1836211-A1 | MACROLIDES | Pfizer Products Incorporated (US) | 2007-09-26 | — | — | EP | claimed |
| WO-2006067589-A1 | MACROLIDES | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212168-A1 | ENDOCYCLIC PYRIMIDINONE COMPOUNDS, AND PREPARATION METHODS, COMPOSITIONS AND USE THEREOF | PLA2G1B, PLA2G5, PLA2G4B | KDM4A 3149/4885KDM4B 3522/4885KDM5C 2313/4885 |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | HAVCR2, AADAC, DNPEP | KDM4A 412/4885KDM4B 926/4885KDM5C 226/4885 |
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | KDM4A 3308/4885KDM4B 2994/4885KDM5C 3408/4885 |
| US-20230242532-A1 | TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | PLA2G1B, PLA2G5, PLA2G7 | KDM4A 4174/4885KDM4B 3878/4885KDM5C 3847/4885 |
| US-20230271980-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | PLA2G1B, PLA2G4B, PLA2G4A | KDM4A 3609/4885KDM4B 3967/4885KDM5C 3204/4885 |
| US-20230357268-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | PLA2G1B, PLA2G4B, PLA2G5 | KDM4A 3785/4885KDM4B 4066/4885KDM5C 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.